Alnylam Pharma (ALNY) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Piper Jaffray Cuts PT on Alnylam (ALNY) by 45%; Keep 'Overweight'
February 12, 2016 8:26 AM ESTPiper Jaffray analyst, Edward Tenthoff, cut his Alnylam Pharmaceuticals (NASDAQ: ALNY) price target to $102 from $184 which still represents 79% upside from current levels. No change to Overweight rating.
Alnylam ended 2015 with cash of $1.28 billion and guided to end 2016 with >$850 million including a $100 million investment in an RNAi manufacturing facility. The company recently completed enrollment of >200 familial amyloidotic polyneuropathy (FAP) patients in the Phase III APOLLO trial setting up top-line data in 2H:17 and a potential launch in 2018. Alnylam is advancing and expanding its... More
